Please login to the form below
Hodgkin lymphoma
This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
Yescarta gains first FDA approval for indolent follicular lymphoma
follicular lymphoma, becoming the first CAR-T cell therapy approved in this indication. ... Specifically, Yescarta (axicabtagene ciloleucel) has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) – a
Latest news
-
bluebird bio to separate oncology and rare diseases units
It will also retain research and development responsibilities for bluebird’s oncology pipeline of cellular therapies, which are focused on non-Hodgkin’s lymphoma, acute myeloid leukaemia, next-generation multiple myeloma
-
FDA sets January decision date for Xalkori in ALK-positive lymphoma
ALCL is a rare form of non-Hodgkin lymphoma, and is characterised either as ALK-positive or ALK-negative disease. ... ALK-positive ALCL is the most common type and is a fast-growing lymphoma that causes T-cell mutations.
-
Keytruda doubles five-year survival rate in NSCLC
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,
-
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
-
World Castleman Disease Day
The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.
bluebird bio to separate oncology and rare diseases units
FDA sets January decision date for Xalkori in ALK-positive lymphoma
Keytruda doubles five-year survival rate in NSCLC
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
World Castleman Disease Day
More from news
Approximately 6 fully matching, plus 208 partially matching documents found.
Latest Intelligence
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Chinese biotech’s global ambitions
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
-
Deal Watch November 2016
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
-
Deal Watch June 2016
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
Growing evidence supports the important role of biosimilars in healthcare
Chinese biotech’s global ambitions
Deal Watch November 2016
Forging a path in specialty care
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
Charles Morris appointed chief development officer at ImmunoGen
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
-
Digital account director
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
